Search

Your search keyword '"Sverre E"' showing total 3,202 results
Start Over Author "Sverre E"

Refine your results

3,202 results on '"Sverre E"'

103. What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence.

Author

Sevre, Kaja, Rist, Aurora, Wachtell, Kristian, Devereux, Richard B, Aurigemma, Gerard P, Smiseth, Otto A, Kjeldsen, Sverre E, Julius, Stevo, Pitt, Bertram, Burnier, Michel, Kreutz, Reinhold, Oparil, Suzanne, Mancia, Giuseppe, and Zannad, Faiez

Subjects
HEART failure, SODIUM-glucose cotransporter 2 inhibitors, VENTRICULAR ejection fraction, ACE inhibitors, ANGIOTENSIN-receptor blockers, TYPE 2 diabetes
Abstract

BACKGROUND More than 90% of patients developing heart failure (HF) have an epidemiological background of hypertension. The most frequent concomitant conditions are type 2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease, all disorders/diseases closely related to hypertension. METHODS HF outcome research focuses on decreasing mortality and preventing hospitalization for worsening HF syndrome. All drugs that decrease these HF endpoints lower blood pressure. Current drug treatments for HF are (i) angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor neprilysin inhibitors, (ii) selected beta-blockers, (iii) steroidal and nonsteroidal mineralocorticoid receptor antagonists, and (iv) sodium-glucose cotransporter 2 inhibitors. RESULTS For various reasons, these drug treatments were first studied in HF patients with a reduced ejection fraction (HFrEF). However, subsequently, they have been investigated and, as we see it, documented as beneficial in HF patients with a preserved left ventricular ejection fraction (LVEF, HFpEF) and mostly hypertensive etiology, with effect estimates assessed partly on top of background treatment with the drugs already proven effective in HFrEF. Additionally, diuretics are given on symptomatic indications. CONCLUSIONS Considering the totality of evidence and the overall need for antihypertensive treatment and/or treatment of hypertensive complications in almost all HF patients, the principal drug treatment of HF appears to be the same regardless of LVEF. Rather than LVEF-guided treatment of HF, treatment of HF should be directed by symptoms (related to the level of fluid retention), signs (tachycardia), severity (NYHA functional class), and concomitant diseases and conditions. All HF patients should be given all the drug classes mentioned above if well tolerated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

104. Women's health, cardiovascular risk and hypertension: the perspective still needs to improve.

Author

Burnier, Michel, Brguljan, Jana, Algharably, Engi Abd Elhady, Kjeldsen, Sverre E., Narkiewicz, Krzysztof, Egan, Brent, Oparil, Suzanne, and Kreutz, Reinhold

Subjects
WOMEN'S health, CARDIOVASCULAR diseases risk factors, MEDICAL misconceptions, GENDER, HYPERTENSION, CARDIOVASCULAR diseases
Abstract

The article discusses the need for improved recognition and promotion of women's health in relation to cardiovascular risk and hypertension. Efforts have been made to increase the participation of women in medical research and incorporate gender and sex analyses into research projects. It highlights the importance of addressing gender-specific health problems and the misconceptions and lack of awareness surrounding cardiovascular diseases in women. The article also emphasizes the underrepresentation of women in clinical trials and the need for sex-specific diagnosis, treatment, and follow-up strategies. Overall, there is a call for a change in perspective and greater consideration of gender aspects in women's health. [Extracted from the article]

Published
2023
Full Text
View/download PDF

106. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension

Author

Williams, Bryan, primary, Mancia, Giuseppe, additional, Spiering, Wilko, additional, Rosei, Enrico Agabiti, additional, Azizi, Michel, additional, Burnier, Michel, additional, Clement, Denis L., additional, Coca, Antonio, additional, de Simone, Giovanni, additional, Dominiczak, Anna F., additional, Kahan, Thomas, additional, Mahfoud, Felix, additional, Redon, Josep, additional, Ruilope, Luis M., additional, Zanchetti, Alberto, additional, Kerins, Mary, additional, Kjeldsen, Sverre E., additional, Kreutz, Reinhold, additional, Laurent, Stéphane, additional, Lip, Gregory Y.H., additional, McManus, Richard, additional, Narkiewicz, Krzysztof, additional, Ruschitzka, Frank, additional, Schmieder, Roland E., additional, Shlyakhto, Evgeny, additional, Tsioufis, Konstantinos P., additional, Aboyans, Victor, additional, and Desormais, Ileana, additional

Published
2019
Full Text
View/download PDF

117. Effect of antihypertensive treatment in isolated systolic hypertension (ISH) : systematic review and meta-analysis of randomised controlled trials

Author

Brunström, Mattias, Carlberg, Bo, Kjeldsen, Sverre E., Brunström, Mattias, Carlberg, Bo, and Kjeldsen, Sverre E.

Abstract

BACKGROUND: Isolated systolic hypertension (ISH) in middle-aged and elderly is associated with high cardiovascular risk, but no randomised controlled trial has assessed the effect of antihypertensive treatment in ISH using today's definition, i.e. systolic blood pressure (SBP) ≥140 mmHg and diastolic blood pressure (DBP) <90 mmHg. METHODS: A systematic review and meta-analysis of randomised controlled trials was performed. Studies with ≥1000 patient-years of follow-up, comparing more intensive versus less intensive BP targets, or active drug versus placebo, were included if the mean baseline SBP was ≥140 mmHg and the mean baseline DBP was <90 mmHg. The primary outcome was major adverse cardiovascular events (MACE). Relative risks from each trial were pooled in random-effects meta-analyses, stratified by baseline and attained SBP level. RESULTS: Twenty-four trials, including 113,105 participants (mean age 67 years; mean blood pressure 149/83 mmHg) were included in the analysis. Overall, treatment reduced the risk of MACE by 9% (relative risk 0.91, 95% confidence interval 0.88-0.93). Treatment was more effective if baseline SBP was ≥160 mmHg (RR 0.77, 95% CIs 0.70-0.86) compared to 140-159 mmHg (RR 0.92, 95% CIs 0.89-0.95; p = 0.002 for interaction), but provided equal additional benefit across all attained SBP levels (RR 0.80, 95% CIs 0.70-0.92 for <130 mmHg, RR 0.92, 95% CIs 0.89-0.96 for 130-139 mmHg, and RR 0.87, 95% CIs 0.82-0.93 for ≥140 mmHg; p = 0.070 for interaction). CONCLUSIONS: These findings support antihypertensive treatment of isolated systolic hypertension, regardless of baseline SBP, to target SBP <140 mmHg and even <130 mmHg if well tolerated.

Published
2023
Full Text
View/download PDF

118. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)

Author

Mancia, G, Kreutz, R, Brunström, M, Burnier, M, Grassi, G, Januszewicz, A, Muiesan, M, Tsioufis, K, Agabiti-Rosei, E, Algharably, E, Azizi, M, Benetos, A, Borghi, C, Hitij, J, Cifkova, R, Coca, A, Cornelissen, V, Cruickshank, J, Cunha, P, Danser, A, Pinho, R, Delles, C, Dominiczak, A, Dorobantu, M, Doumas, M, Fernández-Alfonso, M, Halimi, J, Járai, Z, Jelaković, B, Jordan, J, Kuznetsova, T, Laurent, S, Lovic, D, Lurbe, E, Mahfoud, F, Manolis, A, Miglinas, M, Narkiewicz, K, Niiranen, T, Palatini, P, Parati, G, Pathak, A, Persu, A, Polonia, J, Redon, J, Sarafidis, P, Schmieder, R, Spronck, B, Stabouli, S, Stergiou, G, Taddei, S, Thomopoulos, C, Tomaszewski, M, Van de Borne, P, Wanner, C, Weber, T, Williams, B, Zhang, Z, Kjeldsen, S, Mancia, Giuseppe, Kreutz, Reinhold, Brunström, Mattias, Burnier, Michel, Grassi, Guido, Januszewicz, Andrzej, Muiesan, Maria Lorenza, Tsioufis, Konstantinos, Agabiti-Rosei, Enrico, Algharably, Engi Abd Elhady, Azizi, Michel, Benetos, Athanase, Borghi, Claudio, Hitij, Jana Brguljan, Cifkova, Renata, Coca, Antonio, Cornelissen, Veronique, Cruickshank, J Kennedy, Cunha, Pedro G, Danser, A H Jan, Pinho, Rosa Maria de, Delles, Christian, Dominiczak, Anna F, Dorobantu, Maria, Doumas, Michalis, Fernández-Alfonso, María S, Halimi, Jean-Michel, Járai, Zoltán, Jelaković, Bojan, Jordan, Jens, Kuznetsova, Tatiana, Laurent, Stephane, Lovic, Dragan, Lurbe, Empar, Mahfoud, Felix, Manolis, Athanasios, Miglinas, Marius, Narkiewicz, Krzystof, Niiranen, Teemu, Palatini, Paolo, Parati, Gianfranco, Pathak, Atul, Persu, Alexandre, Polonia, Jorge, Redon, Josep, Sarafidis, Pantelis, Schmieder, Roland, Spronck, Bart, Stabouli, Stella, Stergiou, George, Taddei, Stefano, Thomopoulos, Costas, Tomaszewski, Maciej, Van de Borne, Philippe, Wanner, Christoph, Weber, Thomas, Williams, Bryan, Zhang, Zhen-Yu, Kjeldsen, Sverre E, Mancia, G, Kreutz, R, Brunström, M, Burnier, M, Grassi, G, Januszewicz, A, Muiesan, M, Tsioufis, K, Agabiti-Rosei, E, Algharably, E, Azizi, M, Benetos, A, Borghi, C, Hitij, J, Cifkova, R, Coca, A, Cornelissen, V, Cruickshank, J, Cunha, P, Danser, A, Pinho, R, Delles, C, Dominiczak, A, Dorobantu, M, Doumas, M, Fernández-Alfonso, M, Halimi, J, Járai, Z, Jelaković, B, Jordan, J, Kuznetsova, T, Laurent, S, Lovic, D, Lurbe, E, Mahfoud, F, Manolis, A, Miglinas, M, Narkiewicz, K, Niiranen, T, Palatini, P, Parati, G, Pathak, A, Persu, A, Polonia, J, Redon, J, Sarafidis, P, Schmieder, R, Spronck, B, Stabouli, S, Stergiou, G, Taddei, S, Thomopoulos, C, Tomaszewski, M, Van de Borne, P, Wanner, C, Weber, T, Williams, B, Zhang, Z, Kjeldsen, S, Mancia, Giuseppe, Kreutz, Reinhold, Brunström, Mattias, Burnier, Michel, Grassi, Guido, Januszewicz, Andrzej, Muiesan, Maria Lorenza, Tsioufis, Konstantinos, Agabiti-Rosei, Enrico, Algharably, Engi Abd Elhady, Azizi, Michel, Benetos, Athanase, Borghi, Claudio, Hitij, Jana Brguljan, Cifkova, Renata, Coca, Antonio, Cornelissen, Veronique, Cruickshank, J Kennedy, Cunha, Pedro G, Danser, A H Jan, Pinho, Rosa Maria de, Delles, Christian, Dominiczak, Anna F, Dorobantu, Maria, Doumas, Michalis, Fernández-Alfonso, María S, Halimi, Jean-Michel, Járai, Zoltán, Jelaković, Bojan, Jordan, Jens, Kuznetsova, Tatiana, Laurent, Stephane, Lovic, Dragan, Lurbe, Empar, Mahfoud, Felix, Manolis, Athanasios, Miglinas, Marius, Narkiewicz, Krzystof, Niiranen, Teemu, Palatini, Paolo, Parati, Gianfranco, Pathak, Atul, Persu, Alexandre, Polonia, Jorge, Redon, Josep, Sarafidis, Pantelis, Schmieder, Roland, Spronck, Bart, Stabouli, Stella, Stergiou, George, Taddei, Stefano, Thomopoulos, Costas, Tomaszewski, Maciej, Van de Borne, Philippe, Wanner, Christoph, Weber, Thomas, Williams, Bryan, Zhang, Zhen-Yu, and Kjeldsen, Sverre E

Abstract

Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis (Greece), Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine (Turkey), Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering (Poland), Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos (Greece), Kazuomi Kario (Japan), Vasilios Kotsis (Greece), Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack (UK), Paolo Mulatero (Italy), Dike B. Ojji (Nigeria), Sungha Park (South Korea), Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz (Poland), Venkata Ram (India), Ramiro Sanchez (Argentina), Markus Schlaich (Australia), Alta Schutte (Australia), Cristina Sierra (Spain), Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios (Greece), Bruno Trimarco (Italy), Thomas Unger (The Netherlands), Bert-Jan van den Born (The Netherlands), Anna Vachulova (Slovak Republic), Agostino Virdis (Italy), Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton (USA), Jiri Widimsky (Czech Republic), Jacek Wolf (Poland), Grégoire Wuerzner (Switzerland), Eugene Yang (USA), Yuqing Zhang (China).

Published
2023

128. Directly Observed Therapy in Hypertension (DOT-HTN)

Author

Hjørnholm, Ulla, primary, Aamodt, Mikaela, additional, Larstorp, Anne Cecilie, additional, Fadl Elmula, Fadl Elmula M., additional, Høieggen, Aud, additional, Andersen, Marit Helen, additional, and Kjeldsen, Sverre E., additional

Published
2018
Full Text
View/download PDF

136. The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug

Author

Suzanne Oparil, Michel Burnier, Sverre E. Kjeldsen, and Krzysztof Narkiewicz

Subjects
Denervation, medicine.medical_specialty, business.industry, medicine.drug_class, Blood Pressure, General Medicine, Kidney, Treatment Outcome, Blood pressure, Treatment modality, Internal medicine, Hypertension, Internal Medicine, Cardiology, Humans, Medicine, Sympathectomy, Cardiology and Cardiovascular Medicine, business, Antihypertensive drug, Antihypertensive Agents
Abstract

Renal denervation (RDN) may be a new treatment modality for patients with hypertension. Initially, efforts to test the efficacy of RDN in lowering blood pressure (BP) have focussed on patients with...

Published
2021

137. TIME to face the reality about evening dosing of antihypertensive drugs in hypertension

Author

Sverre E. Kjeldsen, Brent M. Egan, Krzysztof Narkiewicz, Reinhold Kreutz, Michel Burnier, Suzanne Oparil, and Giuseppe Mancia

Subjects
Humans, Antihypertensive Agents, Hypertension/drug therapy, Blood Pressure, Circadian Rhythm, Hypertension, Internal Medicine, General Medicine, Cardiology and Cardiovascular Medicine
Published
2022

140. Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy

Author

Halvorsen, Lene V., primary, Bergland, Ola U., additional, Søraas, Camilla L., additional, Larstorp, Anne Cecilie K., additional, Hjørnholm, Ulla, additional, Kjær, Vibeke N., additional, Kringen, Marianne K., additional, Clasen, Per‐Erik, additional, Haldsrud, Renate, additional, Kjeldsen, Sverre E., additional, Rostrup, Morten, additional, Fadl Elmula, Fadl Elmula M., additional, Opdal, Mimi S., additional, and Høieggen, Aud, additional

Published
2022
Full Text
View/download PDF

144. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension

Author

Williams, Bryan, Mancia, Giuseppe, Spiering, Wilko, Agabiti Rosei, Enrico, Azizi, Michel, Burnier, Michel, Clement, Denis L., Coca, Antonio, de Simone, Giovanni, Dominiczak, Anna, Kahan, Thomas, Mahfoud, Felix, Redon, Josep, Ruilope, Luis, Zanchetti, Alberto, Kerins, Mary, Kjeldsen, Sverre E., Kreutz, Reinhold, Laurent, Stephane, Lip, Gregory Y.H., McManus, Richard, Narkiewicz, Krzysztof, Ruschitzka, Frank, Schmieder, Roland E., Shlyakhto, Evgeny, Tsioufis, Costas, Aboyans, Victor, and Desormais, Ileana

Published
2018
Full Text
View/download PDF

147. Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis

Author

Persu, Alexandre, Gordin, Daniel, Jacobs, Lotte, Thijs, Lutgarde, Bots, Michiel L., Spiering, Wilko, Miroslawska, Atena, Spaak, Jonas, Rosa, Ján, de Jong, Mark R., Berra, Elena, Fadl Elmula, Fadl Elmula M., Wuerzner, Gregoire, Taylor, Alison H.M., Olszanecka, Agnieszka, Czarnecka, Danuta, Mark, Patrick B., Burnier, Michel, Renkin, Jean, Kjeldsen, Sverre E., Widimský, Jiří, Elvan, Arif, Kahan, Thomas, Steigen, Terje K., Blankestijn, Peter J., Tikkanen, Ilkka, and Staessen, Jan A.

Published
2018
Full Text
View/download PDF

148. TIME to face the reality about evening dosing of antihypertensive drugs in hypertension.

Author

Kjeldsen, Sverre E., Egan, Brent M., Narkiewicz, Krzysztof, Kreutz, Reinhold, Burnier, Michel, Oparil, Suzanne, and Mancia, Giuseppe

Subjects
*ANTIHYPERTENSIVE agents, *PATIENT compliance, *BLOOD pressure, *HYPERTENSION, *MORNING
Abstract

The TIME study investigated whether taking blood pressure (BP) medications in the evening improves cardiovascular outcomes compared to taking them in the morning. The study involved 21,104 participants from the United Kingdom and found no difference in the primary outcome between the two dosing groups. There were also no differences in secondary outcomes or between pre-specified subgroups. The study concluded that patients can take their BP medications whenever it is convenient for them. However, adherence to medication is proven to be worse at bedtime, so taking medication in the morning is recommended. [Extracted from the article]

Published
2023
Full Text
View/download PDF

150. Missing Verification of Source Data in Hypertension Research

Author

Brunström, Mattias, Kjeldsen, Sverre E., Kreutz, Reinhold, Gjesdal, Knut, Narkiewicz, Krzysztof, Burnier, Michel, Oparil, Suzanne, and Mancia, Giuseppe

Subjects
article retraction, chronotherapy, Commentaries, blood pressure, antihypertensive agents, drug therapy
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results